• Recruiting

NCT05014646: Phase 2: Leflunomide for High-Risk Smoldering MM in African-Am. & European-Am. Patients

Updated: May 23

NCT05014646: Phase 2: Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients


leflunomide

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients


This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.


Sponsor:

City of Hope Medical Center


Collaborator:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT05014646


Official Title: Phase 2 Trial of Leflunomide in African-American and European-American Patients With High-Risk Smoldering Multiple Myeloma

First Posted : August 20, 2021


Click here for details on ClinicalTrials.gov

 

Drug: Cholestyramine

Drug: Leflunomide

 

Leflunomide


Leflunomide (Code C1128)

4-Isoxazolecarboxamide, 5-Methyl-N-(4-(trifluoromethyl)phenyl)-

Arava

Leflunomide

LEFLUNOMIDE

leflunomide

SU101

 

Locations:


United States, California

United States, Michigan

United States, North Carolina


Posts Archive